Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy J Kinsella

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
The Journal of Biological Chemistry|January 29, 2003
Synthesis and functional analyses of nuclear clusterin, a cell death proteinKonstantin S Leskov, Dmitry Y Klokov, Jing Li, et al.
AORN Journal|March 7, 2003
Using intraoperative radiation therapy--a case studyMary Ann Domanovic, Malika Ouzidane, Rod J Ellis, et al.
Molecular Cancer Therapeutics|May 2, 2006
Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescenceTao Yan, Yuji Seo, Jane E Schupp, et al.
Cancer Journal (Sudbury, Mass.)|September 12, 2003
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivityMei-Ling Kuo, Hwa-Shin Hwang, Patrick R Sosnay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyriboseYuji Seo, Tao Yan, Jane E Schupp, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2007
Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitizationTimothy J Kinsella, Michael T Kinsella, Seongwon Hong, et al.
Molecular Cancer Therapeutics|September 16, 2004
CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responsesTao Yan, Anand B Desai, James W Jacobberger, et al.
International Journal of Radiation Oncology, Biology, Physics|February 11, 2009
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patientsYuji Seo, Michael T Kinsella, Harry L Reynolds, et al.
Radiation Research|October 20, 2010
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancersCharles A Kunos, Tomas Radivoyevitch, John Pink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancerCharles A Kunos, Steven Waggoner, Vivian von Gruenigen, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
The Journal of Biological Chemistry|January 29, 2003
Synthesis and functional analyses of nuclear clusterin, a cell death proteinKonstantin S Leskov, Dmitry Y Klokov, Jing Li, et al.
AORN Journal|March 7, 2003
Using intraoperative radiation therapy--a case studyMary Ann Domanovic, Malika Ouzidane, Rod J Ellis, et al.
Molecular Cancer Therapeutics|May 2, 2006
Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescenceTao Yan, Yuji Seo, Jane E Schupp, et al.
Cancer Journal (Sudbury, Mass.)|September 12, 2003
Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivityMei-Ling Kuo, Hwa-Shin Hwang, Patrick R Sosnay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 2004
Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyriboseYuji Seo, Tao Yan, Jane E Schupp, et al.
Cancer Chemotherapy and Pharmacology|June 15, 2007
Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitizationTimothy J Kinsella, Michael T Kinsella, Seongwon Hong, et al.
Molecular Cancer Therapeutics|September 16, 2004
CHK1 and CHK2 are differentially involved in mismatch repair-mediated 6-thioguanine-induced cell cycle checkpoint responsesTao Yan, Anand B Desai, James W Jacobberger, et al.
International Journal of Radiation Oncology, Biology, Physics|February 11, 2009
Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patientsYuji Seo, Michael T Kinsella, Harry L Reynolds, et al.
Radiation Research|October 20, 2010
Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancersCharles A Kunos, Tomas Radivoyevitch, John Pink, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2010
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancerCharles A Kunos, Steven Waggoner, Vivian von Gruenigen, et al.
Pageof 7